Macrophage Therapeutics to Expand Efforts Into CNS Diseases
March 20 2015 - 3:11PM
Business Wire
- Initiative based on data that targeted
delivery technology crosses blood brain barrier -
Macrophage Therapeutics, Inc., a subsidiary of Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB), today announced that
data from an ongoing human study indicates that Navidea’s Manocept™
technology platform has the ability to safely cross the blood brain
barrier without losing its ability to deliver its payload to the
intended target. Based on this data and on the advice of the
Company’s newly formed Scientific Advisory Board (SAB), Macrophage
Therapeutics will expand the SAB to include members with specific
expertise in central nervous system diseases.
The blood brain barrier has proven to be a significant obstacle
to treating many diseases of the central nervous system. In an
imaging study using the Manocept targeted delivery system, lesions
on the other side of the blood brain barrier were observed. Many of
the leading diseases of the central nervous system such as
Alzheimer’s and Parkinson’s diseases as well as autoimmune CNS
diseases such as Multiple Sclerosis and ALS have pathologies that
can in part be attributed to over active macrophages, the target
for Manocept delivery technology.
“We are encouraged by the early, albeit limited, data that
suggests that Manocept technology traverses the blood brain
barrier, opening the potential to create groundbreaking therapies
in areas such as Alzheimer's, Parkinson's, ALS, and other diseases
that have been difficult to treat. We believe ultimately the safest
and most effective way to treat chronic diseases, such
as Alzheimer's, will be through targeted delivery," said
Michael Goldberg, M.D., CEO of Macrophage Therapeutics. "We look
forward to working with our soon to be expanded scientific advisory
board to further characterize our technology's capabilities in the
broad CNS disease category."
About Macrophage TherapeuticsMacrophage Therapeutics, a
newly created subsidiary of Navidea Biopharmaceuticals, Inc.
(NAVB), is developing therapeutics using the patented Manocept
immunotherapy platform licensed from Navidea to target over-active
macrophages implicated in cancer, cardiovascular, central nervous
system, autoimmune, antiviral, and skin diseases. Manocept
specifically targets CD206, or mannose receptor prevalent on
over-active macrophages. The technology enables highly specific
targeted delivery of active (either existing or yet to be
developed) agents that can modulate the activity of over-active
macrophages that have been implicated in many diseases. Targeted
delivery should significantly enhance a given compound’s efficacy
and safety.
About Navidea Biopharmaceuticals Inc.Navidea
Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical
company focused on the development and commercialization of
precision diagnostics, therapeutics and radiopharmaceutical agents.
Navidea is developing multiple precision-targeted products and
platforms including Manocept™, NAV4694, and NAV5001, to help
identify the sites and pathways of undetected disease and enable
better diagnostic accuracy, clinical decision-making, targeted
treatment and, ultimately, patient care. Lymphoseek® (technetium Tc
99m tilmanocept) injection, Navidea’s first commercial product from
the Manocept platform, was approved by the FDA in March 2013 and by
the EMA in November 2014. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel
radiopharmaceutical agents and therapeutics and advancing the
Company’s pipeline through global partnering and commercialization
efforts. For more information, please visit www.navidea.com.
The Private Securities Litigation Reform Act of 1995 (the Act)
provides a safe harbor for forward-looking statements made by or on
behalf of the Company. Statements in this news release, which
relate to other than strictly historical facts, such as statements
about the Company’s plans and strategies, expectations for future
financial performance, new and existing products and technologies,
anticipated clinical and regulatory pathways, and markets for the
Company’s products are forward-looking statements within the
meaning of the Act. The words “believe,” “expect,” “anticipate,”
“estimate,” “project,” and similar expressions identify
forward-looking statements that speak only as of the date hereof.
Investors are cautioned that such statements involve risks and
uncertainties that could cause actual results to differ materially
from historical or anticipated results due to many factors
including, but not limited to, the Company’s continuing operating
losses, uncertainty of market acceptance of its products, reliance
on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited
product line and distribution channels, competition, limited
marketing and manufacturing experience, risks of development of new
products, regulatory risks and other risks detailed in the
Company’s most recent Annual Report on Form 10-K and other
Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking
statements.
Macrophage Therapeutics, Inc.Michael M. Goldberg, M.D.,
201-608-5218mgoldberg@macrophagetherapeutics.comorNavidea
BiopharmaceuticalsBrent Larson, Executive VP & CFO,
614-822-2330orSharon Correia, Associate Director, Corporate
Communications, 978-655-2686
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024